Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | PPP5C | P53041 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10182466 | 1.00 | CA1 (0.57) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL12429067 | 1.00 | CA1 (0.57) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL14605408 | 1.00 | CA1 (0.57) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL14817675 | 1.00 | CA1 (0.57) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL15588618 | 1.00 | CA1 (0.57) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL16661388 | 1.00 | CA1 (0.57) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL15326594 | 1.00 | CA1 (0.57) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL14853701 | 1.00 | CA1 (0.57) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL13222912 | 1.00 | CA1 (0.57) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL4203567 | 0.95 | CA1 (0.55) | CA1CA2CA9LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2809678-B1 | AN EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM | RELIABLE BIOPHARMACEUTICAL CORP (US) | 2017-03-22 | — | — | EP | disclosed |
| US-8987430-B2 | Efficient and scalable process for the manufacture of fondaparinux sodium | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130261291-A1 | EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2013-10-03 | — | — | US | disclosed |
| US-8420790-B2 | Efficient and scalable process for the manufacture of Fondaparinux sodium | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120116066-A1 | EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116066-A1 | EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM | F11, F10, F2 | CA1 817/4885CA2 519/4885CA9 465/4885 |
| US-20130261291-A1 | EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM | F11, F10, F2 | CA1 817/4885CA2 519/4885CA9 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.